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Background: PNPLA3 polymorphisms have been proposed as a useful tool to stratify NAFLD patients for their risk of disease progression Our aim was to evaluate the impact of PNPLA3 genotype on long-term clinical outcomes and survival in a longitudinal multicentre study.

Methods: 515 Caucasian patients underwent a liver biopsy for clinical suspicion of NAFLD in centres in Italy (Turin, Milan, Palermo) and the United Kingdom (Newcastle). PNPLA3 rs738409 genotyping was performed at the time of liver biopsy Patients have then undertaken regular visits for routine care and clinical events were recorded by clinicians.

Results: 467 patients (91%) were “non-cirrhotic” (F0-F3), while 48 patients (9%) were defined
as “cirrhotic” (F4), but without clinical signs or complications Overall, 72% of patients were heterozygous or homozygous for the mutation (CC 28%; CG 45%; GG 28%) After a median
follow up of 88 months, 45 patients had liver-related events, 8 developed HCC, 53 had cardiovascular events while 8 patients died Considering the entire population, F4 at baseline
was the only independent predictor of mortality [HR 8.48 (1,3-54,5) p=0,02)], of liver events [HR 4.7 (2,2-10,2) p<0,00)] and HCC [HR 31.8 (4,4-227,2) p=0,001]. In non-cirrhotic patients, disease progression, represented by liver-related events, was identified by the degree of fibrosis (F3 vs F0/1/2 HR 2,5 p=0,01) but not by BMI, diabetes or PNPLA3 mutations, when considered as single risk factors However, the combination of PNPLA3 CG/GG and F3 at baseline significantly increased the risk of morbidity [CG/F3: HR 2.6 (1,2-5,6) p=0,015 and GG/F3: HR 3.2 (1,1-10,8) p=0,05]. Cardiovascular events were predicted by the combination of PNPLA3-GG and F3
[HR 3.3 (1,3-8,4) p=0,013] and by diabetes at baseline [HR 2 6 (1,5-4,7) p=0,001] The combination of CG/GG and F3 showed a trend in predicting HCC [HR 8,9 (0,8-98), p=0,07], although not significant. At the survival analysis in non-cirrhotic population, two patients died, both of them with fibrosis F3 and carrying the GG polymorphism [HR 44,3 (3,9-498,9) p=0,002].

Conclusion: In this large longitudinal multicentre study, the combination of PNPLA3 mutations and F3 predicts clinical outcomes in non-cirrhotic NAFLD patients. These findings further underline the importance and the potential prognostic value of PNPLA3 polymorphisms in the natural history of non-alcoholic fatty liver disease.

